PREDICTIVE AND PROGNOSTIC
INFORMATION WITHIN 72 HOURS FOR
PATIENTS WITH NSCLC
PREDICTIVE AND PROGNOSTIC
72 HOURS FOR PATIENTS
How do disease aggressiveness and patient immune response impact your treatment decisions and patient conversations?
VeriStrat® testing provides blood-based predictive and prognostic proteomic information for patients with non-small cell lung cancer (NSCLC) who test negative for EGFR mutations (EGFR wild-type) or whose EGFR mutation status is unknown.1-4, 7 The VeriStrat test measures a patient’s response to a growing tumor and the chronic activation of complex proteomic pathways known to be associated with aggressive cancer.5 VeriStrat can identify which patients are likely to benefit from 1st-line platinum doublet therapy,1,2 and is predictive of therapeutic benefit from EGFR-TKI’s.3,4 Additionally, patients with a VeriStrat Good status experience a better overall prognosis.1-5
VeriStrat® provides prognostic and predictive information for patients with NSCLC
VeriStrat is clinically validated to inform treatment decisions at multiple points throughout the continuum of care. Recent studies support that the vast majority of patients want to have conversations with their physicians surrounding life expectancy, and become an active participant in planning their care6. VeriStrat results can facilitate patient-physician conversations about rapid treatment, prognosis, life expectancy and care preferences. The information provided by VeriStrat is also prognostic of response to first-line standard of care platinum doublet therapy, and predictive of therapeutic benefit from EGFR-TKI’s.
VeriStrat Testing Measures Complex Proteomic Pathways to Inform Treatment Decisions
HOW IT WORKS
Biodesix Lung Reflex® Blood-based Results in 72 Hours Expedite Time to Treatment for NSCLC Patients17
Biodesix Lung Reflex® integrates GeneStrat® and VeriStrat® testing from one blood draw for real-time measurement of genomic and proteomic biomarkers. Biodesix Lung Reflex provides fast, blood-based results and saves tissue for other testing, such as the tissue-based PD-L1 expression test*.
For newly diagnosed patients with non-small cell lung cancer (NSCLC), GeneStrat testing detects actionable mutations to inform targeted therapies for NSCLC. Patients with EGFR positive results are candidates for targeted therapies. Patients with EML4-ALK, ROS1, RET or BRAF mutations are also targeted therapy candidates. Patients with EGFR negative results will reflex to VeriStrat testing to identify aggressive tumor growth and facilitate patient-physician conversations about treatment, prognosis, and care preferences.
Clinical data supports that patients with a VeriStrat Good result are likely to derive benefit from platinum-based therapy, while those with a VeriStrat Poor result are less likely to respond to platinum-based therapy. PD-L1 tissue results, available from multiple vendors, may be considered for these patients, depending on patient history and other factors. For patients who express PD-L1 at ≥50%, single-agent immunotherapy may be a lower toxicity option. For those who express PD-L1 at <50%, more aggressive treatment through novel therapies and combinations, such as a platinum doublet with immunotherapy (immunotherapy triplet), may be a treatment choice. Additionally, broad molecular profiling to identify rare mutations may present options for alternate therapies or clinical trials.
For monitoring progression on EGFR TKI therapy, GeneStrat provides sensitive EGFR T790M detection from blood, with no tissue re-biopsy needed. Patients with an EGFR T790M positive result are candidates for third generation EGFR-TKI therapy.
For monitoring progression of patients with EGFR negative results, VeriStrat provides important prognostic information and is also predictive of therapeutic benefit from EGFR-TKIs.
*PD-L1 tissue testing is not available through Biodesix. Testing can be conducted through multiple vendors; turnaround time for results may vary.
1. Vansteenkiste JF, et al. Poster at: The American Society of Clinical Oncology (ASCO); Chicago, IL; 2012.
2. Grossi, F, et al. Presented at: European Society of Medical Oncology (ESMO) 2014; Madrid, Spain.
3. Gregorc V, et al. The Lancet Oncology. 2014;15(7):713-721.
4. Carbone DP, et al. Journal of Thoracic Oncology. 2012;7(11):1653-1660.
5. Taguchi F, et al. J Natl Cancer Inst. 2007;99(11):838-846.
6. J Clin Oncol 33:3809-3816
7. The VeriStrat test is a proprietary, patent and trademark protected test only available from Biodesix, Inc.